Influenza vaccine viruses and the development of seasonal vaccines: A Japanese perspective.
Autor: | Kato H; Immunization Office, Health Service Division, Health Service Bureau, Ministry of Health, Labour and Welfare of Japan, 1-2-2, Kasumigaseki, Chiyoda-ku, Tokyo 100-8916, Japan., Hozawa T; Influenza Technical Committee, The Japan Association of Vaccine Industries, 2-14-4, Uchikanda, Chiyoda-ku, Tokyo 101-0047, Japan. Electronic address: takao-hozawa@denka.co.jp., Fukushima W; Department of Public Health, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan; Research Center for Infectious Disease Sciences, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. Electronic address: wakaba@omu.ac.jp., Nobusawa E; Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashi-murayama, Tokyo 208-0011, Japan. Electronic address: nobusawa@nih.go.jp., Hirota Y; Clinical Epidemiology Research Center, SOUSEIKAI Medical Group (Medical Co. LTA), 3-6-1, Kashii-teriha, Higashi-ku, Fukuoka 813-0017, Japan. Electronic address: hiro8yoshi@lta-med.com. |
---|---|
Jazyk: | angličtina |
Zdroj: | Vaccine [Vaccine] 2023 Jul 12; Vol. 41 (31), pp. 4625-4631. Date of Electronic Publication: 2023 Jun 07. |
DOI: | 10.1016/j.vaccine.2023.05.070 |
Abstrakt: | In Japan, the Ministry of Health, Labour and Welfare (MHLW) designates one specific virus strain for each component of the quadrivalent seasonal influenza vaccine, and four domestic manufacturers produce egg-based influenza vaccines with the same formulation (inactivated, split-virus) using uniform vaccine strains. Thus, discussions of the development of effective seasonal influenza vaccines so far has focused solely on the antigenic match between the vaccine strains and epidemic viruses. However, in 2017, the Japanese selection system of vaccine viruses demonstrated that even a candidate vaccine virus that is antigenically similar to the predicted circulating viruses is not necessarily suitable for vaccine production, given lower productivity of the vaccine. Taking this experience into account, the MHLW reformed the scheme of vaccine strain selection in 2018, and instructed the Vaccine Epidemiology Research Group created by the MHLW to probe how the virus strains for the seasonal influenza vaccine should be selected in Japan. In this context, a symposium, entitled "Issues of the Present Seasonal Influenza Vaccines and Future Prospects", was held as part of the 22nd Annual Meeting of the Japanese Society for Vaccinology in 2018, and subjects related to the influenza vaccine viruses were discussed among relevant administrators, manufacturers, and researchers. This report summarizes the presentations given at that symposium in order to convey the present scheme of vaccine virus selection, the evaluation of the resulting vaccines, and the efforts at new vaccine formulation in Japan. Notably, from March 2022, the MHLW has launched a discussion of the merits of the seasonal influenza vaccines produced by foreign manufacturers. Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: ‘Takao Hozawa is an employee of Denka Co., Ltd. in Tokyo, Japan. All other authors declare that they are free of competing interests.’ (Copyright © 2023 Elsevier Ltd. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |